Susquehanna International Group
ARCT icon

Susquehanna International Group’s Arcturus Therapeutics ARCT Stock Holding History

Susquehanna International Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$634K Buy
82,100
+51,000
+164% +$372K ﹤0.01% 9052
2025
Q4 		$191K Sell
31,100
-88,600
-74% -$957K ﹤0.01% 10927
2025
Q3 		$2.21M Buy
119,700
+91,900
+331% +$1.48M ﹤0.01% 5565
2025
Q2 		$362K Sell
27,800
-5,200
-16% -$61.5K ﹤0.01% 9915
2025
Q1 		$349K Sell
33,000
-19,900
-38% -$316K ﹤0.01% 9717
2024
Q4 		$898K Sell
52,900
-20,900
-28% -$393K ﹤0.01% 7237
2024
Q3 		$1.71M Buy
73,800
+8,500
+13% +$182K ﹤0.01% 5598
2024
Q2 		$1.59M Sell
65,300
-95,100
-59% -$2.88M ﹤0.01% 5546
2024
Q1 		$5.42M Buy
160,400
+18,700
+13% +$663K ﹤0.01% 3516
2023
Q4 		$4.47M Buy
141,700
+21,500
+18% +$511K ﹤0.01% 3894
2023
Q3 		$3.07M Sell
120,200
-78,800
-40% -$2.43M ﹤0.01% 4338
2023
Q2 		$5.71M Buy
199,000
+74,300
+60% +$2.02M ﹤0.01% 3315
2023
Q1 		$2.99M Buy
124,700
+44,000
+55% +$789K ﹤0.01% 4335
2022
Q4 		$1.37M Sell
80,700
-37,700
-32% -$657K ﹤0.01% 5484
2022
Q3 		$1.75M Sell
118,400
-29,800
-20% -$500K ﹤0.01% 5205
2022
Q2 		$2.33M Sell
148,200
-23,900
-14% -$469K ﹤0.01% 4589
2022
Q1 		$4.64M Buy
172,100
+39,800
+30% +$1.02M ﹤0.01% 3754
2021
Q4 		$4.9M Buy
132,300
+1,700
+1% +$69.3K ﹤0.01% 3773
2021
Q3 		$6.24M Sell
130,600
-22,700
-15% -$1.02M ﹤0.01% 3579
2021
Q2 		$5.19M Sell
153,300
-28,200
-16% -$955K ﹤0.01% 3980
2021
Q1 		$7.5M Sell
181,500
-89,500
-33% -$5.33M ﹤0.01% 3238
2020
Q4 		$11.8M Buy
271,000
+96,300
+55% +$6.52M ﹤0.01% 2308
2020
Q3 		$7.5M Sell
174,700
-90,900
-34% -$4.51M ﹤0.01% 2557
2020
Q2 		$12.4M Buy
265,600
+183,200
+222% +$6.31M ﹤0.01% 1899
2020
Q1 		$1.12M Buy
82,400
+42,500
+107% +$544K ﹤0.01% 5135
2019
Q4 		$434K Buy
39,900
+7,300
+22% +$76.4K ﹤0.01% 7265
2019
Q3 		$335K Buy
32,600
+18,900
+138% +$204K ﹤0.01% 8060
2019
Q2 		$129K Buy
+13,700
New +$101K ﹤0.01% 9478
2018
Q1 		– Sell
-12,300
Closed -$98K – 9271
2017
Q4 		$98K Buy
12,300
+10,800
+720% +$97.1K ﹤0.01% 8699
2017
Q3 		$11K Buy
+1,500
New +$11.3K ﹤0.01% 8683
2017
Q2 		– Sell
-2,371
Closed -$19K – 9147
2017
Q1 		$19K Sell
2,371
-8,372
-78% -$77.5K ﹤0.01% 8732
2016
Q4 		$158K Sell
10,743
-1,786
-14% -$26.7K ﹤0.01% 8816
2016
Q3 		$217K Buy
12,529
+1,372
+12% +$44.3K ﹤0.01% 7451
2016
Q2 		$351K Buy
11,157
+1,257
+13% +$39.6K ﹤0.01% 6705
2016
Q1 		$263K Sell
9,900
-2,914
-23% -$98.7K ﹤0.01% 7472
2015
Q4 		$563K Buy
12,814
+5,114
+66% +$230K ﹤0.01% 6531
2015
Q3 		$326K Sell
7,700
-3,829
-33% -$201K ﹤0.01% 7890
2015
Q2 		$528K Sell
11,529
-6,428
-36% -$295K ﹤0.01% 7538
2015
Q1 		$708K Buy
17,957
+5,028
+39% +$221K ﹤0.01% 6448
2014
Q4 		$338K Sell
12,929
-37,442
-74% -$1.19M ﹤0.01% 7929
2014
Q3 		$5.44M Buy
50,371
+48,885
+3,290% +$6.37M ﹤0.01% 2882
2014
Q2 		$180K Buy
+1,486
New +$179K ﹤0.01% 9149

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's ARCT Position: Q1 2026 in Review

Susquehanna International Group increased its Arcturus Therapeutics (ARCT) stake by 173% in Q1 2026, buying an estimated $943K and bringing the position to 204,014 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #6743.

Susquehanna International Group first reported a position in ARCT in Q3 2014 and has held it in 43 quarters since. The position peaked at $9.84M in Q3 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Susquehanna International Group held 204,014 shares of Arcturus Therapeutics worth $1.57M as of Q1 2026.
  • Susquehanna International Group bought 129,285 Arcturus Therapeutics shares in Q1 2026, an estimated $943K.
  • Arcturus Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6743 holding.
  • Susquehanna International Group first reported a position in Arcturus Therapeutics in Q3 2014 and has held it in 43 quarters since.
  • Susquehanna International Group's Arcturus Therapeutics position peaked at $9.84M in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.